Getinge AB (GTN0) AI Stock Analysis

0 Followers

Getinge AB

(Frankfurt:GTN0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Recurring and high-margin mixRecurring revenue at about two-thirds of sales provides a meaningful base of ongoing demand, while the 70% high-margin mix and stronger disposable exposure can support profitability. This should make earnings less dependent on individual capital-equipment projects over the next several quarters.

Negative Factors

Life Science weaknessContinued weakness in washer, isolator and sterilizer products is a durable drag on the Life Science segment, with positive bioprocessing and service performance not fully offsetting declines. Lower volumes also reduce operating leverage, limiting the segment’s contribution to group growth.

Getinge AB (GTN0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 7.60B
Dividend Yield: 1.81%
Average Volume (3M): 21
Price to Earnings (P/E): 27.1
Beta (1Y): 0.74
Revenue Growth: -1.20%
EPS Growth: 41.26%
Country: Germany
Employees: 12,118
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Getinge AB Business Overview & Revenue Model

Company Description

Getinge AB (publ) is a prominent global medical technology provider, delivering comprehensive products and solutions primarily to operating rooms, intensive care units, and sterilization departments. The company operates through three distinct segmen...

Getinge AB Earnings Call Summary

Earnings Call Date:Oct 21, 2026(Q3-2026)|% Change Since:8.77%|Next Earnings Date:Jan 26, 2027

Earnings Call SentimentPositive

The call was predominantly positive. The company reported organic sales and order growth, improved margins, strong free cash flow, a solid balance sheet, record-high customer satisfaction, product-launch momentum and reiterated full-year guidance. These strengths were partly offset by continued Life Science weakness, elevated quality costs, balloon-pump capacity constraints, the surgical perfusion phaseout, regulatory timing and uncertainty around Q4 deliveries, tariffs and geopolitical conditions.

Positive Updates

Organic Sales and Order Intake Growth

Third-quarter net sales grew 2.1% organically, with positive development in most business areas, while order intake increased 2.6% organically.

Negative Updates

Life Science Decline in Washer, Isolator and Sterilizer Products

Life Science organic order intake declined slightly because positive performance in bioprocessing and service did not fully offset the continuing decline in the washer, isolator and sterilizer subsegment. Organic net sales also fell slightly, despite robust Sterile Transfer growth.

Company Guidance

Getinge reiterated its expectation for organic net sales growth to be in the range of 3% to 5% for 2026, adjusted for the phaseout of surgical perfusion, which is still expected to have net sales in 2026, declining from about SEK 250 million to SEK 50 million; year-to-date organic growth was 2.5%, and Q4 performance is expected to take the company into the span of 3% to 5%, although the lower part of the guidance span is easier and much more realistic than the upper part. The company’s adjusted EBITA margin was 15.6% on a rolling 12-month basis, 15.8% normalized excluding tariffs, and 14.5% excluding the tariff refund of SEK 381 million in Q2 and Q3 of 2026, versus an adjusted EBITA margin span of 16% to 19% by the end of 2028. Cost release is expected from the second half of this year, mainly impacting 2027 and 2028, while quality-related costs are expected to follow a gradual step down, with the decline definitely larger in '27 compared to '26, and then larger again in 2028; CardioSave’s approval time is still expected to be 6 to 9 months.

Getinge AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:GTN0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MDT	81Outperform	$131.58B	25.15	10.60%	2.78%	9.77%	12.28%
GEHC	79Outperform	$37.54B	17.51	19.85%	0.17%	6.87%	-2.26%
ABT	67Neutral	$187.95B	40.19	9.11%	2.32%	10.00%	-66.06%
PHG	67Neutral	$29.39B	27.22	8.44%	3.26%	―	―
BSX	64Neutral	$64.27B	18.71	13.87%	―	8.88%	25.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

DE:GTN0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:GTN0	Getinge AB	24.80	5.87	31.00%
ABT	Abbott Laboratories	108.52	-18.36	-14.47%
BSX	Boston Scientific	44.34	-57.42	-56.43%
PHG	Koninklijke Philips N.V.	30.34	3.25	12.01%
MDT	Medtronic	102.86	9.67	10.38%
GEHC	Ge Healthcare Technologies Inc.	83.02	12.53	17.78%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Getinge AB AI Stock Analysis